Completed PHASE1 INTERVENTIONAL 11-arm NCT03929016

Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Subjects

Sponsor: Drugs for Neglected Diseases

Conditions Cutaneous Leishmaniases Visceral Leishmaniasis

Interventions DNDI-0690 Placebo of DNDI-0690

Updated 7 times since 2019 Last updated: Dec 16, 2022 Started: Apr 4, 2019 Primary completion: Dec 6, 2019 Completion: Jul 2, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cutaneous Leishmaniases and Visceral Leishmaniasis and is currently completed. Drugs for Neglected Diseases leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Feb 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Mar 2021 — Jan 2023 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE1
May 2019 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Drugs for Neglected Diseases
Wellcome Trust

Data source: Drugs for Neglected Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom